Anemia in adults due to decreased red blood cell production
- Stanley L Schrier, MD
Stanley L Schrier, MD
- Editor-in-Chief — Hematology
- Section Editor — Myeloproliferative Disorders; Red Blood Cell Disorders
- Professor of Medicine
- Stanford University School of Medicine
A variety of disorders are associated with anemia due to decreased red cell production (ie, hypoproliferative anemia). This situation is simplistically identified by the finding of a low corrected absolute reticulocyte count (reticulocytopenia). Thus, if a normal corrected absolute reticulocyte count is 25,000 to 75,000/microL (1.0 ± 0.5 percent of the five million red cells/microL), a corrected absolute reticulocyte count below 25,000/microL indicates poor red cell production. (See "Approach to the adult patient with anemia", section on 'Reticulocyte count'.)
There are, however, several important caveats to the interpretation of the reticulocyte count:
●A reticulocyte count of 27,000/microL (ie, at the lower limit of normal) in an anemic patient does not mean that production is normal for that patient.
●Suppose a patient is losing blood due to hemolysis or blood loss at a rate five times normal and the reticulocyte increase is only three times normal. In this setting, impaired production is contributing to the anemia even though the corrected absolute reticulocyte count is three times normal.
This topic reviews the major causes of hypoproliferative anemia associated with a low reticulocyte count and a normal or increased MCV (ie, normocytic or macrocytic hypoproliferative anemias). Iron deficiency anemia, a hypoproliferative anemia usually associated with a low MCV (microcytic hypoproliferative anemia), is discussed in detail separately. (See "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults".)
- Zingraff J, Drüeke T, Marie P, et al. Anemia and secondary hyperparathyroidism. Arch Intern Med 1978; 138:1650.
- Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71:3594.